Nicoletta Testoni

List of Publications by Year
in descending order

163 papers	5,587 citations	71102 41 h-index	85541 71 g-index
163 all docs	163 docs citations	163 times ranked	4426 citing authors

#	Article	IF	Citations
1	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. European Journal of Haematology, 2020, 105, 47-55.	2.2	4
2	Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting. Blood, 2020, 136, 14-15.	1.4	0
3	Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. Cancers, 2019, 11, 1951.	3.7	17
4	A Maturation Index Defines Newly Diagnosed Multiple Myeloma Patients with Advanced Immunophenotypic and Molecular Differentiation Profiles Associated with Poor Prognosis. Blood, 2019, 134, 1797-1797.	1.4	0
5	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. Leukemia, 2018, 32, 1609-1620.	7.2	80
6	Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. Stem Cell Research and Therapy, 2018, 9, 271.	5.5	63
7	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2018, 11, 99.	17.0	35
8	A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups. Blood, 2018, 132, 5284-5284.	1.4	0
9	Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells. Haematologica, 2017, 102, 1204-1214.	3.5	8
10	Conjunctival and Limbal Transplantation From the Same Living-Related Bone Marrow Donor to Patients With Severe Ocular Graft-vs-Host Disease. JAMA Ophthalmology, 2017, 135, 1123.	2.5	16
11	Chromothripsis in acute myeloid leukemia: Biological features and impact on survival. Leukemia, 2017, , .	7.2	3
12	Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia.. Journal of Clinical Oncology, 2017, 35, 7038-7038.	1.6	2
13	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. Oncotarget, 2017, 8, 29906-29913.	1.8	22
14	Copy number variants signature in two patients with relapsed acute promyelocytic leukemia.. Journal of Clinical Oncology, 2017, 35, e23207-e23207.	1.6	0
15	Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia.. Journal of Clinical Oncology, 2017, 35, 11622-11622.	1.6	0
16	Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia.. Journal of Clinical Oncology, 2017, 35, 11611-11611.	1.6	0
17	<scp>FGFR</scp>1 and <scp>KAT6A</scp> rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features. American Journal of Hematology, 2016, 91, E14-6.	4.1	4
18	Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML. Expert Opinion on Pharmacotherapy, 2016, 17, 2479-2486.	1.8	3

#	Article	IF	Citations
19	Complex chromosomal rearrangements leading to <scp>MECOM</scp> overexpression are recurrent in myeloid malignancies with various 3q abnormalities. Genes Chromosomes and Cancer, 2016, 55, 375-388.	2.8	5
20	Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. Leukemia and Lymphoma, 2016, 57, 2058-2064.	1.3	12
21	4q12 translocations with <scp>GSX</scp>2 expression identify a <scp>CD</scp>7⁺ acute myeloid leukaemia subset. British Journal of Haematology, 2015, 171, 141-145.	2.5	6
22	Complex karyotype, older age, and reduced firstâ€line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with longâ€term followâ€up. American Journal of Hematology, 2015, 90, 515-523.	4.1	51
23	Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. Oncotarget, 2015, 6, 31284-31294.	1.8	18
24	FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. BMC Cancer, 2014, 14, 396.	2.6	10
25	The GNAS1 gene in myelodysplastic syndromes (MDS). Leukemia Research, 2014, 38, 804-807.	0.8	4
26	Positron Emission Tomography With Computed Tomographyâ€"Based Diagnosis of Massive Extramedullary Progression in a Patient With High-Risk Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e101-e104.	0.4	10
27	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomideâ€"dexamethasone incorporated into double autologous transplantation. Annals of Hematology, 2013, 92, 1271-1280.	1.8	10
28	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood, 2013, 121, 5138-5144.	1.4	49
29	Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome. Hematology Reports, 2013, 5, 7.	0.8	7
30	BCR-ABL1-Associated Reduction of Beta Catenin Antagonist Chibby1 in Chronic Myeloid Leukemia. PLoS ONE, 2013, 8, e81425.	2.5	14
31	Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis. Blood, 2013, 122, 2622-2622.	1.4	11
32	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. Blood, 2013, 122, 1486-1486.	1.4	0
33	4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. Blood, 2013, 122, 4000-4000.	1.4	0
34	Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience. Blood, 2013, 122, 3911-3911.	1.4	0
35	Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4. Blood, 2013, 122, 1855-1855.	1.4	0
36	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood, 2012, 120, 761-767.	1.4	110

#	Article	IF	Citations
37	A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia. Hematology Reports, 2012, 4, e27.	0.8	1
38	FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. Leukemia Research, 2012, 36, 37-41.	0.8	5
39	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. Blood, 2012, 120, 2601-2601.	1.4	4
40	PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience. Blood, 2012, 120, 1749-1749.	1.4	0
41	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood, 2011, 117, 5591-5599.	1.4	97
42	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood, 2011, 117, 6793-6800.	1.4	98
43	Low-level Bcrâ€“Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. Leukemia Research, 2011, 35, 1527-1529.	0.8	6
44	A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. Leukemia and Lymphoma, 2011, 52, 2329-2335.	1.3	7
45	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. Blood, 2011, 118, 453-453.	1.4	1
46	Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience. Blood, 2011, 118, 4261-4261.	1.4	0
47	The response to imatinib and interferon-Â is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica, 2010, 95, 1415-1419.	3.5	43
48	Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. Cancer Genetics and Cytogenetics, 2010, 199, 76-80.	1.0	28
49	Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration. Leukemia Research, 2010, 34, e246-e247.	0.8	5
50	B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. Leukemia Research, 2010, 34, e282-e285.	0.8	37
51	Rescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological study. British Journal of Haematology, 2010, 149, 70-78.	2.5	9
52	Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis. Journal of Clinical Oncology, 2010, 28, 2748-2754.	1.6	56
53	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. Blood, 2010, 116, 359-359.	1.4	14
54	Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen. Blood, 2010, 116, 4335-4335.	1.4	1

#	Article	IF	Citations
55	Pediatric Therapy In Adult Acute Lymphoblastic Leukemia: Updated Experience of a Single Centre. Blood, 2010, 116, 4338-4338.	1.4	21
56	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. Blood, 2010, 116, 1230-1230.	1.4	2
57	Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMolR) at 12 Months. Blood, 2010, 116, 668-668.	1.4	0
58	Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16811-16816.	7.1	98
59	Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response. Clinical Cancer Research, 2009, 15, 1059-1063.	7.0	28
60	Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. Leukemia Research, 2009, 33, e218-e220.	0.8	9
61	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. Leukemia and Lymphoma, 2009, 50, 114-118.	1.3	9
62	Single or Double Autologous Stem Cell Transplantation Before and After the Era of Novel Agents. Clinical Lymphoma and Myeloma, 2009, 9, S51-S52.	1.4	1
63	Longâ€term followâ€up of 386 consecutive patients with essential thrombocythemia: Safety of cytoreductive therapy. American Journal of Hematology, 2009, 84, 215-220.	4.1	70
64	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica, 2009, 94, 205-212.	3.5	73
65	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood, 2009, 113, 3428-3434.	1.4	59
66	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34â^' cell population with intrinsic resistance to imatinib. Blood, 2009, 114, 5191-5200.	1.4	62
67	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood, 2009, 113, 4497-4504.	1.4	173
68	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood, 2009, 114, 4939-4943.	1.4	62
69	Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood, 2009, 114, 4933-4938.	1.4	203
70	AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood, 2009, 114, 3024-3032.	1.4	156
71	High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.. Blood, 2009, 114, 2176-2176.	1.4	1
72	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. Blood, 2009, 114, 2205-2205.	1.4	8

#	Article	IF	Citations
73	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. Blood, 2009, 114, 860-860.	1.4	3
74	CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.. Blood, 2009, 114, 2174-2174.	1.4	0
75	Acute promyelocytic leukemia with amplification of PML-RARÎ± rearrangement: Clinical implications. Leukemia Research, 2008, 32, 1941-1943.	0.8	3
76	Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. Hematology, 2008, 13, 1-12.	1.5	2
77	Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica, 2008, 93, 1792-1796.	3.5	91
78	Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML. Journal of Clinical Oncology, 2008, 26, 106-111.	1.6	48
79	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-Â: 5-year outcome. Haematologica, 2008, 93, 770-774.	3.5	53
80	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. Haematologica, 2008, 93, 1017-1024.	3.5	22
81	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. Blood, 2008, 112, 181-181.	1.4	19
82	Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. Blood, 2008, 112, 185-185.	1.4	13
83	Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score. Blood, 2008, 112, 3190-3190.	1.4	4
84	Identification and Molecular Characterization of Two Recurrent Genomic Deletions (Type A and Type) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Behalf of the GIMEMA ALL Working Party. Blood, 2008, 112, 428-428.	1.4	0
85	Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability.. Blood, 2008, 112, 1497-1497.	1.4	0
86	NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. Haematologica, 2007, 92, 1268-1269.	3.5	54
87	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica, 2007, 92, 401-404.	3.5	172
88	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRÂ-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica, 2007, 92, 1173-1179.	3.5	198
89	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica, 2007, 92, 101-105.	3.5	57
90	Case?control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. British Journal of Haematology, 2007, 136, 87-95.	2.5	20

#	Article	IF	Citations
91	Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. European Journal of Haematology, 2007, 80, 071202152247002-???.	2.2	4
92	A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.. Blood, 2007, 110, 26-26.	1.4	4
93	Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. Leukemia and Lymphoma, 2006, 47, 469-472.	1.3	24
94	Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid Leukemia Who Obtained a Complete Cytogenetic Response Within 1 Year of Imatinib Therapy and Those Who Achieved Such a Response After 12 Months of Treatment. Journal of Clinical Oncology, 2006, 24, 454-459.	1.6	42
95	Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients. Clinical Cancer Research, 2006, 12, 3037-3042.	7.0	90
96	Poor Outcome With Front-Line Autologous Transplantation in t(4;14) Multiple Myeloma: Low Complete Remission Rate and Short Duration of Remission. Journal of Clinical Oncology, 2006, 24, e4-e5.	1.6	31
97	Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosomeâ€"Positive Leukemia. Journal of Clinical Oncology, 2006, 24, e51-e52.	1.6	61
98	Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).. Blood, 2006, 108, 3081-3081.	1.4	10
99	Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).. Blood, 2006, 108, 836-836.	1.4	17
100	FLT-3 Activity and Its Response to Drugs Can Be Determined in AML Blast Cells by FLT-3 Phosphorylation Status Using Flow Cytometry.. Blood, 2006, 108, 2308-2308.	1.4	0
101	NPM Mutations and Not FLT3 Mutations Are a Potential Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia.. Blood, 2006, 108, 2016-2016.	1.4	0
102	Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.. Blood, 2006, 108, 4805-4805.	1.4	0
103	Prevalence and Prognostic Significance of FLT3 Mutations in Acute Myeloid Leukemia: Association of ITDs with Poor Outcome in Patients with Normal Cytogenetics.. Blood, 2006, 108, 2017-2017.	1.4	0
104	Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood, 2005, 106, 35-39.	1.4	333
105	Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. British Journal of Haematology, 2005, 131, 172-179.	2.5	43
106	Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. Experimental Hematology, 2005, 33, 1521-1530.	0.4	44
107	ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2005, 23, 4100-4109.	1.6	350
108	Fludarabine Based Regimen (FLAI) Is an Effective Treatment for Induction of Multidrug Resistant Pgp-Positive Acute Myeloid Leukemia Patients.. Blood, 2005, 106, 1857-1857.	1.4	6

#	Article	IF	Citations
109	Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.. Blood, 2005, 106, 375-375.	1.4	3
110	Superior Complete Remission/Very Good Partial Remission Rate with Peri-Transplant Administration of Thalidomide-Dexamethasone for Newly Diagnosed Multiple Myeloma.. Blood, 2005, 106, 5474-5474.	1.4	0
111	Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. Blood, 2005, 106, 1100-1100.	1.4	0
112	Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. Blood, 2005, 106, 1098-1098.	1.4	4
113	Comparison of Cytogenetics and Interphase Fluorescence In Situ Hybridization in Newly Diagnosed Ph+ Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate. A Study by the GIMEMA Working Party on CML. On Behalf of GWP on CML.. Blood, 2005, 106, 4857-4857.	1.4	0
114	Chromosome 9 and 22 Breakpoints Cluster Regions Definition of Deleted Sequences on der(9) in Chronic Myeloid Leukemia.. Blood, 2005, 106, 4842-4842.	1.4	0
115	Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia. Cancer Genetics and Cytogenetics, 2004, 151, 85-86.	1.0	1
116	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood, 2004, 103, 2284-2290.	1.4	69
117	Imatinib and pegylated human recombinant interferon-Î±2b in early chronic-phase chronic myeloid leukemia. Blood, 2004, 104, 4245-4251.	1.4	96
118	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement treated with Imatinib.. Blood, 2004, 104, 1507-1507.	1.4	1
119	Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.. Blood, 2004, 104, 4655-4655.	1.4	0
120	Imatinib in the Treatment of CML Patients â‰¥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.. Blood, 2004, 104, 2935-2935.	1.4	0
121	Heterogeneous Chromosomal Mechanisms Generating the 5â€²RUNX1/3â€²CBFA2T1 Gene in Acute Myeloid Leukemia.. Blood, 2004, 104, 4272-4272.	1.4	0
122	Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML.. Blood, 2004, 104, 4672-4672.	1.4	0
123	Interleukin-12 Gene Expression into Acute Myeloid Leukemia-Derived Dendritic Cells Overcomes T-Cell Functional Impairment Induced by Leukemic Microenvironment.. Blood, 2004, 104, 1816-1816.	1.4	6
124	Superiority of First-Line Thalidomide-Dexamethasone over Vincristine-Doxorubicin-Dexamethasone in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.. Blood, 2004, 104, 1489-1489.	1.4	4
125	First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica, 2004, 89, 826-31.	3.5	133
126	Novel translocations that disrupt the plateletâ€derived growth factor receptor Î² (PDGFRB) gene in BCRâ€“ABLâ€negative chronic myeloproliferative disorders. British Journal of Haematology, 2003, 120, 251-256.	2.5	87

#	Article	IF	Citations
127	The cytogenetic response as a surrogate marker of survival. Seminars in Hematology, 2003, 40, 56-61.	3.4	22
128	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood, 2003, 102, 1588-1594.	1.4	113
129	The cytogenetic response as a surrogate marker of survival. Seminars in Hematology, 2003, 40, 56-61.	3.4	3
130	Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood, 2002, 99, 443-449.	1.4	133
131	A randomized study of interferon-Î± versus interferon-Î± and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood, 2002, 99, 1527-1535.	1.4	158
132	Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. Experimental Hematology, 2002, 30, 126-134.	0.4	41
133	Chronic myeloid leukemia and interferon-Î±: a study of complete cytogenetic responders. Blood, 2001, 98, 3074-3081.	1.4	309
134	Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. British Journal of Haematology, 2000, 109, 722-728.	2.5	30
135	All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia. European Journal of Haematology, 2000, 64, 139-144.	2.2	23
136	Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma. Journal of Clinical Oncology, 2000, 18, 2273-2281.	1.6	153
137	Quantitative Evaluation of BCR-ABL Amount of Transcript Post Mobilization with G-CSF of Peripheral Blood Stem Cells from Chronic Myeloid Leukemia Patients in Cytogenetic Response. Leukemia and Lymphoma, 2000, 39, 113-120.	1.3	2
138	Characterization of 12p molecular events outside ETV6 in complex karyotypes of acute myeloid malignancies. British Journal of Haematology, 1999, 107, 340-346.	2.5	19
139	Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro. European Journal of Haematology, 1998, 60, 161-165.	2.2	22
140	Granulocytic Sarcomas: Clinical, Diagnostic and Therapeutical Aspects. Leukemia and Lymphoma, 1997, 24, 349-353.	1.3	15
141	Â«FingerprintingÂ» of HLA-DQA by polymerase chain reaction and heteroduplex analysis. Molecular and Cellular Probes, 1996, 10, 123-127.	2.1	2
142	Flang (Fludarabine + Cytosine Arabinoside + Novantrone + G-CSF) Induces Partial Remission in Lymphoid Blast Transformation of Ph⁺Chronic Myelogenous Leukaemia. Leukemia and Lymphoma, 1996, 22, 173-176.	1.3	8
143	The presence of lymphoidâ€associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. Stem Cells, 1995, 13, 428-434.	3.2	29
144	Does the Type of BCR/ABL Junction Predict the Survival of Patients with Ph¹-Positive Chronic Myeloid Leukemia?. Leukemia and Lymphoma, 1995, 16, 231-236.	1.3	5

#	Article	IF	Citations
145	Fourâ€chromosomes complex translocations in acute promyelocytic leukemia: Description of two cases. European Journal of Haematology, 1994, 52, 129-133.	2.2	14
146	The type of BCR/ABL junction does not predict the survival of patients with Ph1-positive chronic myeloid leukaemia. British Journal of Haematology, 1993, 84, 265-268.	2.5	19
147	t(8;14)(q11;q32) in acute lymphoid leukemia. Cancer Genetics and Cytogenetics, 1993, 67, 55-58.	1.0	12
148	Interferon-Alpha Effects on Stromal Compartment of Normal and Chronic Myeloid Leukemia Hematopoiesis. Leukemia and Lymphoma, 1993, 11, 113-118.	1.3	16
149	Structural Organization of BCR-ABL Gene in Chronic Phase and Blast Transformation in Chronic Myeloid Leukemia Patients. Leukemia and Lymphoma, 1993, 11, 51-56.	1.3	7
150	In Vitro Activity of Alpha-Interferon on Granulocyte-Macrophage Precursors in Chronic Myeloid Leukemia (CML): Correlation with Clinical Responsiveness. Leukemia and Lymphoma, 1992, 6, 155-160.	1.3	4
151	Cytogenetic events after bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia. Leukemia Research, 1991, 15, 289-296.	0.8	5
152	Molecular and cytogenetic studies of a patient with philadelphia-negative,BCR-positive chronic myeloid leukemia and t(12;12)(q13;p12). Genes Chromosomes and Cancer, 1990, 1, 284-288.	2.8	3
153	Treatment of Ph+ chronic myeloid leukemia by gamma interferon. Blut, 1989, 59, 15-20.	1.2	9
154	Cytogenetic and molecular studies in patients with chronic myeloid leukemia and variant Philadelphia translocations. Cancer Genetics and Cytogenetics, 1989, 42, 191-201.	1.0	21
155	CYTOGENETIC AND MOLECULAR ANALYSES IN PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA. British Journal of Haematology, 1988, 69, 424-426.	2.5	2
156	Philadelphia-positive acute myelomonocytic leukemia with inversion of chromosome 16 and eosinobasophils. American Journal of Hematology, 1988, 27, 69-71.	4.1	23
157	Chromosome studies in patients with Philadelphia chromosome-positive chronic myeloid leukemia submitted to bone marrow transplantationâ€"Results of a European cooperative study. Cancer Genetics and Cytogenetics, 1987, 26, 5-13.	1.0	26
158	Chromosome studies in patients with acute nonlymphocytic or acute lymphocytic leukemia submitted to bone marrow transplantationâ€"Results of a European cooperative study. Cancer Genetics and Cytogenetics, 1987, 26, 51-58.	1.0	17
159	Cytogenetic analyses in 89 patients with secondary hematologic disordersâ€"Results of a cooperative study. Cancer Genetics and Cytogenetics, 1987, 26, 65-74.	1.0	28
160	Inversions of chromosome 12 in human malignancies. Cancer Genetics and Cytogenetics, 1987, 28, 113-118.	1.0	17
161	Vimentin and keratin intermediate filaments expression by K562 leukemic cell line. Leukemia Research, 1986, 10, 29-33.	0.8	14
162	Chromosome 12 rearrangement with breakage at the p11 level in hematologic disorders: Report of four cases. Cancer Genetics and Cytogenetics, 1985, 15, 309-314.	1.0	8

#	Article	IF	Citations
163	Acute nonlymphocytic leukemias and dysmyelopoietic syndromes in patients treated for Hodgkin's lymphoma. Cancer Genetics and Cytogenetics, 1983, 9, 217-226.	1.0	12